🔴 Moderna is trading 4.03% down in pre-market with no confirmed catalyst

Moderna is trading 4.03% down at $195.26 in pre-market on September 30; no reliable report directly ties the move to a new announcement.

• A Delaware judge recently allowed Bayer’s mRNA patent lawsuits against Moderna and other vaccine makers to proceed.
• The ruling was procedural and did not decide infringement or patent validity. Reuters reported the decision but did not link it to the pre-market decline.